Head and neck carcinoma cell lines are sensitive to vinflunine in vitro

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 4363-4367

  Erjala, Kaisa ^a   Raitanen, Misa ^a   Kulmala, Jarmo ^a   Grénman, Reidar ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Chemosensitivity in vitro; Clonogenic assay; Head and neck squamous cell carcinoma; Vinflunine

Indexed keywords

NAVELBINE; VINCA ALKALOID; VINFLUNINE;

ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL SURVIVAL; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; DRUG SENSITIVITY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; METASTASIS INHIBITION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HEAD AND NECK NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; VINBLASTINE;

EID: 27944501612     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Browman GP, Hodson DI, Mackenzie RJ, Bestic N and Zuraw L; Cancer Care Ontario Practice Guideline Initiative Head and Neck Cancer Disease Site Group: Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 23(7): 579-589, 2001.
2. Jordan MA, Thrower D and Wilson L: Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res 51(8): 2212-2222, 1991.
3. Johnson SA, Harper P, Hortobagyi GN and Pouillart P: Vinorelbine: an overview. Cancer Treat Rev 22(2): 127-142, 1996.
4. Kruczynski A, Colpaert F, Tarayre JP, Mouillard P, Fahy J and Hill BT: Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated vinca alkaloid. Cancer Chemother Pharmacol 41(6): 437-447, 1998.
5. Hill BT, Fiebig HH, Waud WR, Poupon MF, Colpaert F and Kruczynski A: Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 35(3): 512-520, 1999.
6. Lansford CD, Grénman R, Bier H, Somers KD, Kim SY, Whiteside TL, Clayman GL, Welkoborsky H-J and Carey TE: Human Cell Culture Vol II, Chapter 28. Masters JRW and Palsson B (eds.). Great Britain, Kluwer Academic Publishers, pp. 185-255, 1999.
7. Erjala K, Pulkkinen J, Kulmala J, Alanen K and Grénman R: Head and neck squamous cell carcinoma is highly sensitive to vinorelbine in vitro. Anticancer Res 22(6A): 3135-3142, 2002.
8. Grénman R, Burk D, Virolainen E, Wagner JG, Lichter AS and Carey TE: Clonogenic cell assay for anchorage-dependent squamous cell carcinoma cell lines using limiting dilution. Int J Cancer 44: 131-136, 1989.
9. Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy J and Hill BT: Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated vinca alkaloid. Biochem Pharmacol 55(5): 635-648, 1998.
10. Ngan VK, Bellman K, Hill BT, Wilson L and Jordan MA: Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 60(1): 225-232, 2001.
11. Pourroy B, Carre M, Honore S, Bourgarel-Rey V, Kruczynski A, Briand C and Braguer D: Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway. Mol Pharmacol 66(3): 580-591, 2004.
12. Bennouna J, Fumoleau P, Armand JP, Raymond E, Campone M, Delgado FM, Puozzo C and Marty M: Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 14(4): 630-637, 2003.
13. Holwell SE, Hill BT and Bibby MC: Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer 84(2): 290-295, 2001.
14. Kruczynski A and Hill BT: Vinflunine, the latest vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 40(2): 159-173, 2001.
15. Etievant C, Kruczynski A, Barret JM, Tait AS, Kavallaris M and Hill BT: Markedly diminished drug resistance-inducing properties of vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother Pharmacol 48(1): 62-70, 2001.
16. Barret JM, Etievant C and Hill BT: In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol 45(6): 471-476, 2000.
17. Simoens C, Korst AE, De Pooter CM et al: Vinflunine and radiation: a promising radiosensitizing combination? Proc Am Assoc Cances Res 45: abstr. 840, 2004.
18. Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA and Wilson L: Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 60: 5045-5051, 2000.
19. Lobert S, Ingram JW, Hill BT and Correia JJ: A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 53: 908-915, 1998.
20. Tan EH, Bennouna J, Ottensmeier C, O'Brien M, Kosmidis P, Pinel M-C, Perrot O and Douillard J-Y: Vinflunine (VFL) in advanced non-small cell lung cancer (NSCLC): preliminary results of a phase II study in patients (pts) previously treated with a platinum based regimen. Proc Am Soc Clin Oncol 22: 36 (abstr. 2739), 2003.
21. Fumoleau P, Campone M, Vorobiof D, Casado M, Ruff P, Cortes-Funes H, Khalfallah S, Caroff I and Colin C: Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure. Proc Am Soc Clin Oncol 23: 1 (abstr, 542), 2004.